GM1 Gangliosidosis Treatment Market Size
The global GM1 gangliosidosis treatment market was valued at USD 186.26 million in 2025 and is projected to reach nearly USD 626.86 million by 2033, growing at a CAGR of 16.6% during the forecast period from 2026 to 2033.
The global GM1 gangliosidosis treatment market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. Rising lysosomal storage disorders, research and development and government investments in pharmaceuticals and biotechnology are among the key drivers impacting GM1 gangliosidosis treatment globally. After the challenging year of 2020, the GM1 gangliosidosis treatment industry showed decent resilience and adaptability.
Government investments in lysosomal storage disorders, particularly in developing economies, will continue to drive utilization of gene therapy and boost the global GM1 gangliosidosis treatment market. The global GM1 gangliosidosis treatment industry is placing increasing emphasis on better management of GM 1 gangliosidosis. The respective initiatives includes the use of other treatment, such as enzyme replacement therapies for treatment of gangliosidosis.
The GM1 gangliosidosis type 1 (infantile), accounts for over one third of the market share. Similarly, the North America dominates the GM1 gangliosidosis treatment market, capturing the largest market share of over 1/3rd. The region’s rapid investments in healthcare and rising major players in the GM1 gangliosidosis treatment market globally, makes it the largest market share holder. United States has the largest pool of manufacturers as well as consumers.
Market Scope
| Metrics | Details |
| CAGR | High |
| Size Available for Years | 2023-2033 |
| Forecast Period | 2026-2033 |
| Data Availability | Value (US$) |
| Segments Covered | Type, Treatment, End User, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, South America and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report - Request for Sample
Market Dynamics
Growing Research and Development by Researchers
Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high income levels, investments and infrastructure development. Several countries have experienced substantial demand for GM1 gangliosidosis treatment, reflecting their expanding healthcare industries. Rising research and development for the same will be a crucial factor driving the growth of the market.
On May 30, 2023, in patient plasma, urine, and cerebral fluid (CSF), two pentasaccharide biomarkers, H3N2b and H3N2a, were raised more than 18-fold. In the cat model, only H3N2b was discernible, and it was inversely linked with -galactosidase activity. Reduction of H3N2b was seen in the central nervous system, plasma, urine, and CSF samples that were collected from the cat model as well as in the urine, plasma, and CSF samples from a patient after intravenous (IV) AAV9 gene therapy treatment.
The restoration of the normal range of neuropathology in the cat model and the enhancement of clinical results in the patient were appropriately mirrored by the reduction of H3N2b. These findings show that H3N2b is a valuable pharmacodynamic biomarker for GM1 gangliosidosis gene therapy efficacy assessment. The discovery that H3N2b is a frequent biomarker in the cat model and for people with GM1 gangliosidosis raises the possibility that this pentasaccharide can help in the translation of novel therapies from the cat model to humans.
Rising Number of Clinical Outcomes with Positive Outcomes
Rising clinical trials with positive outcomes for treatment of GM1 gangliosidosis will drive the growth of the market in coming period of time. For instance, on December 14, 2022, new interim security, biomarker, and clinical development data from cohorts 1-3 in the Imagine-1 clinical research have been released by Passage Bio, Inc., a trial-stage genetic medicines firm that specializes in developing transformative treatments for illnesses of the central nervous system (CNS). Imagine-1 is a Phase 1/2, international, open-label, dose-escalation research of the intra-cisternal magna (ICM) injection with the AAVhu68 gene therapy PBGM01 in four cohorts of young patients with late or early infantile GM1 Gangliosidosis (GM1).
In the rare and deadly lysosomal storage disease GM1, mutations in the GLB1 gene cause the enzyme beta-galactosidase (-Gal) to function at very low levels. Six treated individuals from the initial three groups are represented in the interim results. Each cohort had three patients: cohort 1 (late infantile, lower dose), cohort 2 (late infantile, heavy dose), and cohort 3 (early infantile, low dose). By the middle of 2023, results for Cohort 4 (early infantile, large dosage) participants should be available.
Challenges Associated with Gene Therapy
For monogenic illnesses like GM1, gene therapy is a possible treatment option. It is difficult to achieve worldwide viral genome distribution or the diffusion of a functioning enzyme across the CNS in hereditary illnesses with neuropathology. The BBB not only prevents medications from being delivered to the brain intravenously, but techniques to get around the BBB through intrathecal or intracranial injections are invasive.
Despite these difficulties, gene therapy has the power to stop the spread of a disease with just one treatment. Only a few of the indications and symptoms of GM1 can currently be treated medically, and even those do not stop the disease from progressing. As a result, some people might think about trying experimental gene therapy.
Limitations Related to the Therapies
SRT in GM1 is dependent on strong GSL biosynthesis inhibitors. SRT may have a smaller effect on clinical disease if ganglioside production is inhibited without a way to degrade previously accumulated substrate. Therefore, it is believed that some residual -gal activity is necessary, limiting the use of SRT to individuals who are not infantile.
Glucosylceramide Synthase, that catalyzes the first committed step of GSL biosynthesis, is inhibited by the N-alkylated imino-sugar derivatives N-butyl-deoxygalactonojirimycin (NB-DGJ) and N-butyl-deoxynojirimycin (NB-DNJ), which has been FDA-approved for therapy of Gaucher disease.
Market Segment Analysis
The global GM1 gangliosidosis treatment market is segmented based on type, treatment, end user and region.
High Advantages of Treatment via Gene Therapy
To possibly treat the infantile, late infantile, or juvenile forms of GM1, gene therapy is being investigated. A functioning clone of the GLB1 gene will be introduced into cells using gene therapy for GM1 utilizing a viral vector. Cells are instructed to produce the ß-gal enzyme by the GLB1 gene. Scientists have figured out a safe way to harness viruses' propensity for entering cells as a vehicle for delivering functional genes. Only curative (intended) genes are supplied because the viral genes have been eliminated.
The objective is to reestablish the way lysosomes work, which is to eliminate and stop the accumulation of hazardous chemicals. There are various ways to provide GM1 gene therapy. One method involves administering an intra-cisterna magna or intracisternal injection near the base of the skull. The fluid-filled region around the brain or spinal cord is where the gene therapy is delivered. A different strategy is to administer the gene therapy intravenously, or into a vein. Then, the bloodstream spreads the gene therapy throughout the body. Clinical studies may vary in their design in a number of ways, including how gene therapy is administered.
Market Geographical Share
North America Accounted for the largest market share in 2025, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment
Due to the rising need for GM1 gangliosidosis treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for GM1 gangliosidosis treatment.
Increasing expenditure on healthcare and rising research studies, advancement of technologies for different treatments of gangliosidosis, and increase in pharmaceutical or biotech business establishment across the region are also contributing to the growth of GM1 gangliosidosis treatment market share of this region.
The key healthcare organizations' and businesses' joint research initiatives are also expected to contribute to the rising demand, as will new product development, which constantly looks to improve present options. The market in this area is growing as people become more aware of various novel treatments such as gene therapy or enzyme replacement therapy. The aforementioned elements further attest to North America's hegemonic position in the world.
North America continues to be a key player in the global GM1 gangliosidosis treatment market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising lysosomal storage disorders have fueled the demand for GM1 gangliosidosis treatment in the region. United States have been proactive in executing several initiatives or researches, stimulating GM1 gangliosidosis treatment demand.
Key Developments
February 2026: Rising advancements in gene replacement therapies and adeno-associated viral vector technologies accelerated innovation in GM1 gangliosidosis treatment across North America and Europe. Major companies including Passage Bio, Sio Gene Therapies, and Axovant Gene Therapies strengthened research activities focused on neurodegenerative lysosomal storage disorders.
January 2026: Increasing investments in rare disease research and orphan drug development across the United States, Germany, Japan, and the United Kingdom improved clinical development pathways for GM1 gangliosidosis therapies. Regulatory agencies expanded support for fast-track and rare pediatric disease designation programs.
December 2025: Growing adoption of genetic screening and advanced diagnostic technologies improved early detection of GM1 gangliosidosis in pediatric populations globally. Hospitals and specialty genetic centers across Europe and North America strengthened integration of next generation sequencing and enzyme activity testing platforms.
November 2025: Expansion of clinical trials evaluating gene therapy and substrate reduction therapy approaches increased treatment development opportunities for GM1 gangliosidosis patients worldwide. Biotechnology companies collaborated with academic research institutions to improve long-term neurological outcomes and disease management strategies.
October 2025: Rising advancements in CNS-targeted delivery systems, biomarker monitoring, and neuroprotective therapeutic approaches improved precision treatment development for GM1 gangliosidosis globally. Research institutions accelerated innovation in blood-brain barrier penetration technologies supporting rare neurological disease therapies.
September 2025: Increasing collaborations between pharmaceutical companies, patient advocacy organizations, and rare disease foundations accelerated awareness programs and global clinical research initiatives. Asia-Pacific regions including Japan and South Korea strengthened investments in genetic disease treatment infrastructure and rare disease registries.
August 2025: Growing healthcare investments and orphan drug incentives across Middle East, Latin America, and Asia-Pacific regions supported expansion of rare disease treatment accessibility and specialized care services. Governments focused on improving reimbursement support and access to advanced genetic therapies for pediatric neurological disorders.
July 2025: Rising demand for personalized medicine, digital patient monitoring, and multidisciplinary neurological care improved long-term disease management for GM1 gangliosidosis patients globally. Healthcare providers increasingly integrated telehealth and remote monitoring solutions into rare disease management programs.
June 2025: Increasing focus on rare pediatric neurological disorders, precision medicine, and advanced genetic therapies supported strong growth in the GM1 gangliosidosis treatment market worldwide. North America maintained market leadership due to strong biotechnology research infrastructure, while Europe and Asia-Pacific emerged as significant growth regions driven by expanding rare disease research initiatives.
Market Companies
The major global players in the market include Passage Bio, Lysogene, Sio Gene Therapies, Inc., BioStrategies LC, Sanofi, AZAFAROS, Dorphan S.A., Idorsia Pharmaceuticals Ltd, SphinCS GmbH and Viatris Inc.
Why Purchase the Report?
- To visualize the global GM1 gangliosidosis treatment market segmentation based on type, treatment, end user and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of GM1 gangliosidosis treatment market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global GM1 gangliosidosis treatment market report would provide approximately 61 tables, 58 figures and 186 Pages.
Target Audience
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
